Detalles de la búsqueda
1.
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
Support Care Cancer
; 20(1): 159-65, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21359879
2.
Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.
Support Care Cancer
; 20(9): 2089-96, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22160485
3.
Disease and treatment burden of psoriasis: examining the impact of biologics.
J Drugs Dermatol
; 10(2): 189-96, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21283925
4.
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
Value Health
; 13(1): 14-7, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-19883404
5.
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
Transfusion
; 49(5): 895-902, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19175548
6.
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
J Manag Care Pharm
; 15(4): 312-22, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19422271
7.
Anaemia and the risk of injurious falls in a community-dwelling elderly population.
Drugs Aging
; 25(4): 325-34, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18361542
8.
Current management of anemia in critically ill patients: analysis of a database of 139 hospitals.
Am J Ther
; 15(5): 423-30, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18806517
9.
Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
Ann Pharmacother
; 42(1): 16-23, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18029428
10.
Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) : a registry for characterizing anaemia management and outcomes in oncology patients.
Clin Drug Investig
; 28(3): 159-67, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18266401
11.
The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
Dis Manag
; 10(1): 37-45, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17309363
12.
Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.
Curr Med Res Opin
; 22(9): 1623-31, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16968565
13.
Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
Curr Med Res Opin
; 22(5): 837-42, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16709305
14.
Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Drugs Aging
; 23(12): 969-76, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17154661
15.
Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review.
Curr Med Res Opin
; 32(7): 1281-90, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27033747
16.
Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
Curr Med Res Opin
; 21(9): 1347-54, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16197652
17.
Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysis.
Clin Drug Investig
; 25(1): 33-48, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-17523745
18.
Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey.
Clin Ther
; 32(2): 238-45, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20206781
19.
Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients.
J Med Econ
; 13(4): 673-80, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21050062
20.
An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.
J Occup Environ Med
; 50(5): 584-9, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18469628